Key facts
- Longbio Pharma’s last known valuation is $277.8M (May 2025).
- It has raised $76.7M; the latest was IPO in Aug 2025.
- Notable investors include Qiming Venture Partners, Oriental Fortune Capital, Highlight Capital, Shanghai Lingang Economic Development, Ancheng Capital — 13 tracked in total.
- Status: In IPO Registration.
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Longbio Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Longbio Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Longbio Pharma
Manufacturer of antibody-based biologics intended for autoimmune and allergic diseases. The company's platform brings drugs such as monoclonal antibody drugs targeting the complement and IgE pathways to both domestic and international markets, offering affordable and high-quality bio-medicines, enabling patients to access more effective and targeted therapies.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2020
- Employees
- 67
- Website
- longbio.com/
- Ownership
- In IPO Registration
Longbio Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Longbio Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Longbio Pharma in its N-PORT filings yet. We sweep new filings monthly.